Business Context and Reporting Period
Company: Daré Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2020
Reporting Period: Specific event date of January 28, 2020.
Business Context: The registrant is an emerging growth company incorporated in Delaware, with common stock trading on the Nasdaq Capital Market under the symbol "DARE".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding regulatory compliance status only.
Material Changes
Regulatory Compliance: On January 28, 2020, Daré Bioscience, Inc. was informed that it had regained compliance with the Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. This resolves a prior non-compliance issue previously reported in a Form 8-K filed on December 26, 2019.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) confirming the regained compliance status.
Risks and Contingencies: The filing addresses the resolution of a listing deficiency risk related to the minimum bid price rule. No new risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of DARE stock to ensure continued compliance with Nasdaq minimum bid price rules.
- Review the press release dated January 30, 2020 (Exhibit 99.1) for additional details on the compliance restoration.
- Check the prior Form 8-K filed on December 26, 2019, to understand the specific hearing and deficiency details that were resolved.
- Confirm the company's status as an emerging growth company for potential reporting exemptions.